Abstract
Non-platinum combinations including gemcitabine and irinotecan (Gemzar; Eli Lilly and Company, Indianapolis, IN) for the management of a variety of malignancies have started to emerge. Gemcitabine and irinotecan are well-tolerated single agents, each with a broad spectrum of antitumor activity. Preclinical data suggests synergy for the two drugs when used in combination. A phase I trial has defined a well-tolerated combination regimen using both drugs on a day-1, -8 schedule every 3 weeks. Phase II data suggest activity for the combination in pancreatic cancer, and a phase III trial of the two-drug combination versus gemcitabine alone is underway in previously untreated pancreatic cancer patients. Other phase II trials evaluating the impact of this combination on a variety of other tumors, such as non-small cell lung, small cell lung, breast, colorectal, and non-Hodgkin's lymphoma, are either forthcoming or in progress.
| Original language | English |
|---|---|
| Pages (from-to) | 34-43 |
| Number of pages | 10 |
| Journal | Seminars in Oncology |
| Volume | 28 |
| Issue number | 3 SUPPL. 10 |
| State | Published - Aug 29 2001 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Beyond pancreatic cancer : Irinotecan and gemcitabine in solid tumors and hematologic malignancies. / Rocha Lima, C. M S; Urbanic, J. J.; Lal, A.; Kneuper-Hall, R.; Brunson, C. Y.; Green, M. R.
In: Seminars in Oncology, Vol. 28, No. 3 SUPPL. 10, 29.08.2001, p. 34-43.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Beyond pancreatic cancer
T2 - Irinotecan and gemcitabine in solid tumors and hematologic malignancies
AU - Rocha Lima, C. M S
AU - Urbanic, J. J.
AU - Lal, A.
AU - Kneuper-Hall, R.
AU - Brunson, C. Y.
AU - Green, M. R.
PY - 2001/8/29
Y1 - 2001/8/29
N2 - Non-platinum combinations including gemcitabine and irinotecan (Gemzar; Eli Lilly and Company, Indianapolis, IN) for the management of a variety of malignancies have started to emerge. Gemcitabine and irinotecan are well-tolerated single agents, each with a broad spectrum of antitumor activity. Preclinical data suggests synergy for the two drugs when used in combination. A phase I trial has defined a well-tolerated combination regimen using both drugs on a day-1, -8 schedule every 3 weeks. Phase II data suggest activity for the combination in pancreatic cancer, and a phase III trial of the two-drug combination versus gemcitabine alone is underway in previously untreated pancreatic cancer patients. Other phase II trials evaluating the impact of this combination on a variety of other tumors, such as non-small cell lung, small cell lung, breast, colorectal, and non-Hodgkin's lymphoma, are either forthcoming or in progress.
AB - Non-platinum combinations including gemcitabine and irinotecan (Gemzar; Eli Lilly and Company, Indianapolis, IN) for the management of a variety of malignancies have started to emerge. Gemcitabine and irinotecan are well-tolerated single agents, each with a broad spectrum of antitumor activity. Preclinical data suggests synergy for the two drugs when used in combination. A phase I trial has defined a well-tolerated combination regimen using both drugs on a day-1, -8 schedule every 3 weeks. Phase II data suggest activity for the combination in pancreatic cancer, and a phase III trial of the two-drug combination versus gemcitabine alone is underway in previously untreated pancreatic cancer patients. Other phase II trials evaluating the impact of this combination on a variety of other tumors, such as non-small cell lung, small cell lung, breast, colorectal, and non-Hodgkin's lymphoma, are either forthcoming or in progress.
UR - http://www.scopus.com/inward/record.url?scp=0034892564&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034892564&partnerID=8YFLogxK
M3 - Article
VL - 28
SP - 34
EP - 43
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - 3 SUPPL. 10
ER -